Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ACLY | P53396 | 1/20 | 0.63 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.57 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308597 | 0.92 | MEN1 (0.72) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22022886 | 0.90 | ACLY (0.72) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1309256 | 0.87 | MEN1 (0.78) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27520745 | 0.86 | KDM4E (0.62) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19511950 | 0.86 | MEN1 (0.63) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9661232 | 0.85 | MEN1 (0.56) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22022901 | 0.85 | ACLY (0.66) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22022883 | 0.85 | ACLY (0.63) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19511952 | 0.85 | MEN1 (0.67) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22022929 | 0.84 | ACLY (0.65) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | MEN1 2312/4885KMT2A 1570/4885ALDH1A1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.